Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Blood (2025) 146 (21): 2608–2611.

https://doi.org/10.1182/blood.2025029391

Published: 2025

Includes: Supplemental data

Journal Articles

Protein degradation of MYC/GSPT1 combined with menin inhibition overcomes resistance to menin inhibition in KMT2A-rearranged Acute Myeloid Leukemia

Shayaun Khazaei, Shreya Nair, Lauren Ostermann, Hideaki Mizuno, Po Yee Mak, Bing Carter, Steffen Boettcher, Liandong Ma, Miriam Garcia, Branko Cuglievan, Alexandra McLean Stevens, Michael Andreeff, Yuki Nishida

Blood (2025) 146 (Supplement 1): 1510.

https://doi.org/10.1182/blood-2025-1510

Published: 2025

Journal Articles

Identifying novel 'druggable’ targets via Npm1A-turboid fusion and mass spectrometry to overcome genetic or adaptive resistance to menin inhibitors in mtNPM1 AML

Christopher Mill, Warren Fiskus, John Davis, Christine Birdwell, Hanxi Hou, Claes Wahlestedt, Jayastu Senapati, Koji Sasaki, Sanam Loghavi, Branko Cuglievan, Tapan Kadia, Naval Daver, Courtney DiNardo, Kapil Bhalla

Blood (2025) 146 (Supplement 1): 1500.

https://doi.org/10.1182/blood-2025-1500

Published: 2025

Journal Articles

Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma

Blood (2025) 146 (Supplement 1): 1852.

https://doi.org/10.1182/blood-2025-1852

Published: 2025

Journal Articles

Positive outcomes associated with stem cell transplantation in pediatric/AYA patients who receive FLAG-IDA-venetoclax for high-risk AML

Irtiza Sheikh, Reeja Raj, Olayinka Okeleji, Samanta Catueno, Aaron Fan, David McCall, Amber Gibson, Miriam Garcia, Jeremy Connors, Michael Roth, Cesar Nunez, Demetrios Petropoulos, Branko Cuglievan, Priti Tewari

Blood (2025) 146 (Supplement 1): 5156.

https://doi.org/10.1182/blood-2025-5156

Published: 2025

Journal Articles

Co-targeting menin and RAS in KMT2A-r/NPM1c AML with activated RTK//RAS/MAPK signaling

Bing Carter, Po Yee Mak, Vakul Mohanty, Xiaogang Wu, Khin The Nu Aye, Ken Chen, Branko Cuglievan, Michael Andreeff

Blood (2025) 146 (Supplement 1): 5060.

https://doi.org/10.1182/blood-2025-5060

Published: 2025

Journal Articles

Next-generation sequencing as a powerful tool for measurable residual disease assessment in pediatrics: Identifying time points of true remission

David McCall, Aline Hittle, Branko Cuglievan, Elias Jabbour, Nicholas Short, Nitin Jain, Samanta Catueno, Miriam Garcia, Cesar Nunez, Michael Roth, Laurie Toepfer, Romeo Torres, Amber Gibson

Blood (2025) 146 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2025-3370

Published: 2025

Journal Articles

Overcoming barriers to clinical trial enrollment among adolescents and young adults with acute myeloid leukemia: Insights from a large academic cancer center

Blood (2025) 146 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2025-4613

Published: 2025

Journal Articles

Post-transplant maintenance with revumenib in children with HOX-driven AML

Blood (2025) 146 (Supplement 1): 3461.

https://doi.org/10.1182/blood-2025-3461

Published: 2025

Journal Articles

Protein degradation of MYC/GSPT1 is a novel treatment modality for aggressive T-cell acute lymphoblastic leukemias

Mikaela Garza, Shayaun Khazaei, Faryal Munir, Phoebe Calkins, Darah Threat, Hideaki Mizuno, Lauren Ostermann, Branko Cuglievan, Miriam Garcia, Liandong Ma, Michael Andreeff, Yuki Nishida

Blood (2025) 146 (Supplement 1): 1539.

https://doi.org/10.1182/blood-2025-1539

Published: 2025

Journal Articles

Clinical, cytogenetic and molecular characteriszation of Mecom- rearranged pediatric de novo Acute Myeloid Leukemia (AML): A retrospective cohort study of the international-berlin-frankfurt-Münster (I-BFM) AML-study group

Blood (2025) 146 (Supplement 1): 1608.

https://doi.org/10.1182/blood-2025-1608

Published: 2025

Journal Articles

Protein expression signatures reveal age-specific risk patterns in B-ALL

Samanta Catueno, Yihua Qiu, Gaye Jenkins, Eduardo de Camargo Magalhaes, Brandon Brown, Rebecca Garris, Branko Cuglievan, Elias Jabbour, Nicholas Short, Terzah Horton, Steven Kornblau

Blood (2025) 146 (Supplement 1): 1593.

https://doi.org/10.1182/blood-2025-1593

Published: 2025

Journal Articles

Cardiac safety of revumenib in children with HOX-driven leukemia: A single-institution cohort

Blood (2025) 146 (Supplement 1): 6950.

https://doi.org/10.1182/blood-2025-6950

Published: 2025

Journal Articles

Multiarm Phase I study of the cyclin dependent kinase (CDK4/6) inhibitor palbociclib in combination for patients with relapsed and refractory acute leukemias

Hannah Goulart, Caitlin Rausch, Elias Jabbour, Abhishek Maiti, David McCall, Naval Daver, Nicholas Short, Naveen Pemmaraju, Musa Yilmaz, Danielle Hammond, Steven Kornblau, Ghayas Issa, Branko Cuglievan, Farhad Ravandi, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 5204.

https://doi.org/10.1182/blood-2025-5204

Published: 2025

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2025-1001

Published: 2025

Journal Articles

Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML

Blood (2025) 146 (Supplement 1): 47.

https://doi.org/10.1182/blood-2025-47

Published: 2025

Journal Articles

Phase II Study of Pedi-Crib: Mini-Hyper-CVD with Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric Patients with B-Cell Lineage Acute Lymphocytic Leukemia

David McCall, Amber Gibson, Miriam B. Garcia, Cesar Nunez, Michael E. Roth, Branko Cuglievan

Blood (2024) 144 (Supplement 1): 1431.1.

https://doi.org/10.1182/blood-2024-212144

Published: 2024

Journal Articles

Identifying ‘Druggable’ Targets and Preclinically Overcoming Non-Genetic/Adaptive Resistance to Menin Inhibitors in AML with MLL1r or mtNPM1

Warren C. Fiskus, Christopher Peter Mill, Jessica Piel, Mike Collins, Murphy Hentemann, Christine Birdwell, Kaberi Das, John A. Davis, Hanxi Hou, Surbhi Sharma, Koji Sasaki, Sanam Loghavi, Branko Cuglievan, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Kapil N. Bhalla

Blood (2024) 144 (Supplement 1): 1373.

https://doi.org/10.1182/blood-2024-206374

Published: 2024

Journal Articles

Mortality after Diagnosis of Cardiovascular Disease in Survivors of Adolescent and Young Adult Lymphoma

Karan Gowda, Medha Gupta, Adrian Aguliar, Carlos Cruz, Elizabeth Rodriguez, Sairah Ahmed, Branko Cuglievan, Efstratios Koutroumpakis, Michael E. Roth, Michelle A.T. Hildebrandt

Blood (2024) 144 (Supplement 1): 5128.

https://doi.org/10.1182/blood-2024-211291

Published: 2024

Journal Articles

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Blood (2024) 144 (Supplement 1): 211.

https://doi.org/10.1182/blood-2024-194384

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Protein degradation of MYC/GSPT1 combined with menin inhibition overcomes resistance to menin inhibition in KMT2A-rearranged Acute Myeloid Leukemia

Identifying novel 'druggable’ targets via Npm1A-turboid fusion and mass spectrometry to overcome genetic or adaptive resistance to menin inhibitors in mtNPM1 AML

Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma

Positive outcomes associated with stem cell transplantation in pediatric/AYA patients who receive FLAG-IDA-venetoclax for high-risk AML

Co-targeting menin and RAS in KMT2A-r/NPM1c AML with activated RTK//RAS/MAPK signaling

Next-generation sequencing as a powerful tool for measurable residual disease assessment in pediatrics: Identifying time points of true remission

Overcoming barriers to clinical trial enrollment among adolescents and young adults with acute myeloid leukemia: Insights from a large academic cancer center

Post-transplant maintenance with revumenib in children with HOX-driven AML

Protein degradation of MYC/GSPT1 is a novel treatment modality for aggressive T-cell acute lymphoblastic leukemias

Clinical, cytogenetic and molecular characteriszation of Mecom- rearranged pediatric de novo Acute Myeloid Leukemia (AML): A retrospective cohort study of the international-berlin-frankfurt-Münster (I-BFM) AML-study group

Protein expression signatures reveal age-specific risk patterns in B-ALL

Cardiac safety of revumenib in children with HOX-driven leukemia: A single-institution cohort

Multiarm Phase I study of the cyclin dependent kinase (CDK4/6) inhibitor palbociclib in combination for patients with relapsed and refractory acute leukemias

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML

Phase II Study of Pedi-Crib: Mini-Hyper-CVD with Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric Patients with B-Cell Lineage Acute Lymphocytic Leukemia

Identifying ‘Druggable’ Targets and Preclinically Overcoming Non-Genetic/Adaptive Resistance to Menin Inhibitors in AML with MLL1r or mtNPM1

Mortality after Diagnosis of Cardiovascular Disease in Survivors of Adolescent and Young Adult Lymphoma

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only